Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-873

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-873 Category Tag

Product Details

Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Interferon beta is a cytokine in the interferon family used to treat multiple sclerosis (MS)

Products Name (INN Index)

Pre-Made Interferon Beta Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC

INN Name

interferon beta

Target

IFNAR1

Format

Recombinant Protein

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IFNB1 (interferon beta 1, IFNB) *a (C38) 22-187

VD LC

IFNB1 (interferon beta 1, IFNB) *a (C38) 22-187

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Biogen,?Inc. (Cambridge MA USA) / Merck Serono?International S.A. (Geneva Switzerland)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IFNAR1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide